Pain Expert Edward Mariano, MD, MAS, Highlights Journavx and the Newly-Approved Nonopioid's Mechanism of Action
Mariano, a well-known researcher in regional anesthesiology and acute pain medicine, talks about the Journavx difference, including the drug's safety profile.
Journavx Approval: Lead Investigator Highlights Pivotal Phase 3 Clinical Trials
Todd Bertoch, MD, reviews the significant findings on relief of pain from the 2 pivotal studies and lauds the remarkable safety profile of the novel nonopoid analgesic Journavx.
FDA Approves Journavx, First-in-Class Nonopioid Analgesic for Moderate-to-Severe Acute Pain
Journavx is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years.
Axsome Therapeutics: FDA Approves Symbravo for Acute Treatment of Migraine
A single oral dose of Symbravo provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy through 24 and 48 hours.
Tezepelumab Misses Primary Endpoint in Phase 2a COURSE Trial of Moderate to Very Severe COPD
Although the study missed the primary endpoint, subgroup analyses found variable efficacy based on baseline BECs, suggesting potential benefits in specific subgroups.
5 Drug Classes Linked to Increased Fall Risk Among Adults with COPD Near End of Life
Furosemide Fails to Reduce Risk of Dangerous de novo Postpartum Hypertension: New Research
Close monitoring for dnPPHTN during the first 2 weeks post-delivery is highly recommended for women determined to be at high risk for the hypertensive disorder of pregnancy.
Investigational Nonopioid Cebranopadol Meets Primary Endpoint in Pivotal Phase 3 ALLEVIATE-1 Clinical Trial
Cebranopadol developer Tris Pharma expects to submit an NDA to the FDA for the dual-NMR agonist to treat moderate-to-severe acute pain later this year.
Tris Pharma's Cebranopadol Shows Low Potential for Misuse in Intranasal Human Abuse Potential Study
The novel dual NMR agonist was scored significantly less "likable" when crushed and taken intranasally compared with oxycodone, the company reported.
Alzheimer Assessment Update: Alzheimer's Association Publishes New Appropriate Use Criteria for Amyloid and Tau PET
Neurocrine Biosciences Launches Phase 3 Registration Program for Osavampator in Major Depressive Disorder
The investigational and potentially first-in-class therapy may enhance AMPA receptor sensitivity to glutamate, enhancing neuronal transmission.
Patient Selection for Lecanemab to Treat Early Alzheimer Dementia: Details with R Scott Turner, PhD, MD
Dr Turner reviews the profile of the individual who is most likely to benefit from lecanemab therapy.
Enobosarm Preserves Lean Body Mass in Older Adults Treated with Semaglutide for Weight Reduction: Topline Phase 2b Data
In preliminary findings of the phase 2b QUALITY trial, 32% of weight loss in the semaglutide group was from lean mass reduction vs 9.4% in the combined semagutide/enobosarm group.
Tapinarof 1% Cream Significantly Improves Patient Reported Outcomes, Including Family QoL, in Atopic Dermatitis
Tapinarof 1% cream when used as topical monotherapy led to statistically significant and sustained improvements in QoL, sleep, and other PROs across age groups.
Lecanemab Monthly IV Maintenance Dosing: Research Highlights with R Scott Turner, PhD, MD
Georgetown University memory disorders expert R Scott Turner, PhD, MD, reviews the science behind approval of lecanemab for monthly maintenance dosing of lecanemab.
FDA Approves Monthly IV Maintenance Dosing of Lecanemab for Adults with Early Alzheimer Dementia: A First in Long-Term Disease Management
Once every four weeks maintenance dosing of lecanemab may be easier for patients and care partners to continue treatment.
3 Studies on Major Depressive Disorder: Physical, Pharmacologic, and Neuromodulatory Interventions Explored
Findings on the efficacy of treatments for MDD include the favorable effects of exercise, of CBT, and the robust outcomes of ECT among neuromodulatory modalities.
Anti-Amyloid Antibodies in Short: R Scott Turner, PhD, MD Explains
The revolutionary medications are the first new treatments for Alzheimer disease to be approved in more than 20 years and the first-ever disease-modifying drugs.
Vaccine Hesitancy in the Chronic Conditions Community: New Survey Findings
People with chronic diseases like COPD or with immunocompromising conditions continue to have reservations about vaccines against flu, COVID-19, and RSV.
Self-Reported Symptoms of Topical Steroid Withdrawal Identified in Study of Atopic Dermatitis
There are no diagnostic criteria for topical steroid withdrawal but patients describe and discuss it on social media. Study authors tapped a deep source of information.
Two Plasma Proteins May Serve as Early Biomarkers for Alzheimer Dementia and Help Explain Sex Differences, Study Suggests
Levels of acetyl-L-carnitine and free carnitine correlated significantly with disease severity, particularly in women with moderate and severe Alzheimer dementia.
Most People Who Monitor Health with Wearable Devices Don't Share Data with Clinicians
Only 25% of people who self-monitor health use the data to inform their physicians.
Landmark International Trial Seeks to Intercept and Prevent Crohn Disease Using Biomarkers
The INTERCEPT project aims to build a blood risk score that can identify individuals with a high risk of developing Crohn disease within 5 years of initial evaluation.
Attitudes Toward Vaccines in the Chronic Conditions Community: Survey Highlights
Hesitancy about vaccination against dangerous communicable diseases remains a public health problem, particularly when the hesitant are living with immunocompromising conditions.
GLP-1 Mimetic Benefits Are Broad, New Study Finds, But Risks Can't Be Ignored
Incretin-mimetics may have even broader application against disease than scientists can predict, but the risks are real, too, according to a study of 2 million.
Ascletis Enters Small Molecule Oral GLP-1 RA Category with Positive Phase 1a Findings in Obesity
The properties of ASC30 may allow the small molecule GLP-1 RA to be formulated as a monthly injection and daily oral tablet, Ascletis said.
Tralokinumab Dosing Every 4 Weeks is Effective Maintenance Regimen for Atopic Dermatitis, Study Suggests
The key factors predicting stable response to tralokinumab every 4 weeks (vs every 2 weeks) were IGA 0/1 and EASI-75, according to a small post hoc analysis.
RSVPreF Reduces Risk of Severe RSV in Older, High-Risk Adults in Large Real-World Study
The new research augments data on efficacy of RSVPreF in older, high-risk adults that was not captured in phase 3 pivotal clinical trials, authors said.
Zyn Nicotine Pouches Get FDA Nod But Not Without Warnings
Agency review determined the pouches to be less harmful to health than cigarettes and an aid to smoking cessation but did not declare the products "safe."
Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial
The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.
